EDIT (Editas Medicine, Inc.) Stock Financials & Earnings | Market Cap Arena

EDIT (Editas Medicine, Inc.) Stock Financials & Earnings | Market Cap Arena

EDITEditas Medicine, Inc.

Mkt Cap$256M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$46M

Net Income (TTM)-$200M

EPS (TTM)-$2.38

Free Cash Flow (TTM)-$166M

Gross Margin100.0%

Op. Margin-428.7%

Net Margin-430.8%

FCF Margin-357.6%

P/S Ratio (TTM)5.5x

P/E Ratio (TTM)—

YoY Rev Growth-24.9%

Employees—

Earnings Reports

Next: Q4 2025 · Mar 11

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$7M	-$45M	-$63M
Q1 23	$10M	-$28M	-$51M
Q2 23	$3M	-$27M	-$44M
Q3 23	$5M	$4M	-$50M
Q4 23	$60M	$59M	-$24M
Q1 24	$1M	-$274K	-$67M
Q2 24	$513K	-$907K	-$72M
Q3 24	$61K	-$2M	-$66M
Q4 24	$31M	$31M	-$47M
Q1 25	$5M	$5M	-$76M
Q2 25	$4M	$4M	-$52M
Q3 25	$8M	$8M	-$25M

Valuation

Quarter	P/S	P/E
Q4 22	13.0x	—
Q1 23	11.2x	—
Q2 23	13.2x	—
Q3 23	10.4x	—
Q4 23	3.3x	—
Q1 24	3.7x	—
Q2 24	3.8x	—
Q3 24	4.1x	—
Q4 24	7.9x	—
Q1 25	7.1x	—
Q2 25	6.6x	—
Q3 25	5.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$36M	-$38M
Q2 23	-$39M	-$40M
Q3 23	-$35M	-$36M
Q4 23	-$22M	-$24M
Q1 24	-$50M	-$52M
Q2 24	-$57M	-$61M
Q3 24	-$53M	-$56M
Q4 24	-$51M	-$51M
Q1 25	-$48M	-$48M
Q2 25	-$50M	-$50M
Q3 25	-$31M	-$31M
Q4 25	-$36M	-$36M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$2M
Q2 23	$1M
Q3 23	$239K
Q4 23	$1M
Q1 24	$2M
Q2 24	$3M
Q3 24	$3M
Q4 24	$540K
Q1 25	$114K
Q2 25	$0
Q3 25	$433K
Q4 25	$60K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	-47.6%	+29.4%
Q1 23	+45.5%	+5.7%
Q2 23	-54.6%	-22.5%
Q3 23	+12604.8%	-3.6%
Q4 23	+818.7%	+20.0%
Q1 24	-88.5%	+12.0%
Q2 24	-82.2%	+54.1%
Q3 24	-98.9%	+18.4%
Q4 24	-49.0%	-8.1%
Q1 25	+310.4%	+18.6%
Q2 25	+597.5%	-23.9%
Q3 25	+12265.6%	-51.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$5M	45.8%
Q2 23	$5M	180.6%
Q3 23	$5M	88.7%
Q4 23	$5M	8.9%
Q1 24	$8M	668.3%
Q2 24	$5M	976.6%
Q3 24	$5M	7872.1%
Q4 24	$4M	13.1%
Q1 25	$3M	64.0%
Q2 25	$3M	74.5%
Q3 25	$2M	29.5%
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 22	$52M	$18M
Q1 23	$38M	$23M
Q2 23	$30M	$17M
Q3 23	$5M	$15M
Q4 23	$68M	$14M
Q1 24	$47M	$19M
Q2 24	$53M	$18M
Q3 24	$48M	$18M
Q4 24	$49M	$16M
Q1 25	$27M	$13M
Q2 25	$16M	$13M
Q3 25	$20M	$12M

Revenue Segments

Quarter	Reportable Segment
Q1 25	$5M
Q2 25	$4M
Q3 25	$8M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$142M	$203M	$344M
Q1 23	$129M	$189M	$318M
Q2 23	$221M	$211M	$432M
Q3 23	$83M	$267M	$350M
Q4 23	$124M	$199M	$323M
Q1 24	$69M	$227M	$296M
Q2 24	$64M	$215M	$279M
Q3 24	$96M	$169M	$265M
Q4 24	$132M	$138M	$270M
Q1 25	$139M	$82M	$221M
Q2 25	$139M	$40M	$179M
Q3 25	$166M	$0	$166M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	69M	+0.1%
Q1 23	69M	+0.2%
Q2 23	71M	+3.6%
Q3 23	82M	+14.4%
Q4 23	82M	+0.1%
Q1 24	82M	+0.3%
Q2 24	82M	+0.5%
Q3 24	82M	+0.2%
Q4 24	83M	+0.2%
Q1 25	83M	+0.5%
Q2 25	84M	+1.6%
Q3 25	90M	+6.7%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	$24K	67
FY 16	$68K	89
FY 17	$123K	112
FY 18	$240K	133
FY 19	$99K	208
FY 20	$386K	235
FY 21	$97K	264
FY 22	$87K	226
FY 23	$295K	265
FY 24	$131K	246
FY 25	$0	20K